Author:
Moja Lorenzo,Huttner Benedikt
Publisher
Springer International Publishing
Reference15 articles.
1. IQVIA Institute for Human Data Science. 2018 and Beyond: Outlook and Turning Points; 2018. https://www.iqvia.com/insights/the-iqvia-institute/reports/2018-and-beyond-outlook-and-turning-points
2. Hassoun-Kheir N, van Werkhoven CH, Dunning J, Jaenisch T, van Beek J, Bielicki J, et al. Perpetual observational studies: new strategies to support efficient implementation of observational studies and randomized trials in infectious diseases. Clin Microbiol Infect. 2022;28:1528–32. https://doi.org/10.1016/j.cmi.2022.07.024.
3. ‘t Hoen EF, Hogerzeil HV, Quick JD, Sillo HB. A quiet revolution in global public health: the world health organization’s prequalification of medicines programme. J Public Health Policy. 2014;35(2):137–61. https://doi.org/10.1057/jphp.2013.53.
4. Executive Board 109/8. WHO medicines strategy Revised procedure for updating WHO’s Model List of Essential Drugs. December 2001. https://apps.who.int/gb/e/e_eb109.html
5. World Health Organization Model List of Essential Medicines – 22nd List, 2021. Geneva: World Health Organization (WHO/MHP/HPS/EML/2021.02). Licence: CC BY-NC-SA 3.0 IGO; 2021. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02